Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Oncology, Support Care, Cognitive Disord...
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is one of the most common cancers in metropolitan France, with over 60,000 new cases in 2023. Mostly a female cancer, it can affect a young population, with around 20% of breast cancers occurring in women under 50. Treatment is mainly based on surgery, chemotherapy, radiotherapy, targeted therapies and hormone therapy. Although chemotherapy is not systematically used, it remains a frequent treatment option. While chemotherapy makes a major contribution to curing cancer, it is also a source of potentially disabling side effects for survivors. Chemotherapy can interfere with the normal functioning of the central nervous system, leading to cognitive impairment. The number of people potentially affected by chemobrain is estimated at several tens of millions worldwide. There is no recommended treatment for people with chemobrain. Several avenues have been explored, with very limited results. Photobiomodulation (PBM) is a non-medicinal treatment technique that combines all the biological, athermic and non-cytotoxic effects of tissue exposure to non-ionizing sources of red and infrared light. Several studies have demonstrated the beneficial effects of cortical stimulation by photobiomodulation on memory (increased angiogenesis, increased oxygenation of brain tissue via vasodilatation, and increased mitochondrial ATP production). These positive biological effects are likely to ameliorate the undesirable effects of chemotherapy, and consequently the post-chemotherapy cognitive disorders that ensue.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Photobiomodulation — 12 sessions of photobiomodulation (1 per week) Visit 1 to 4 : photobiomodulation (NOVOTHOR) + cortical stimulation (VEILIGHT) Visit 5 to 12 : cortical stimulation (VEILIGHT)

Primary Outcomes

  • To compare, among women aged 18 and over who had undergone chemotherapy for breast cancer and had subjective cognitive impairment post-chemotherapy, the rate of those showing improvement in cognitive impairment with or without photobiomodulation (cortica (From enrollment to the end of follow-up visit at 13 weeks (V13 = V12 + 7d +/- 3d))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-13
Completion: 2027-12
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier de Valenciennes
Contact Information
Study Contact:
Lidvine GODAERT, MD
03.27.14.91.19
godaert-l@ch-valenciennes.fr
Interventions
  • Other: Photobiomodulation — 12 sessions of photobiomodulation (1 per week) Visit 1 to 4 : photobiomodulation (NOVOTHOR) + cortical stimulation (VEILIGHT) Visit 5 to 12 : cortical stimulation (VEILIGHT)
Study Locations (1 sites)
Centre Hospitalier de Valenciennes, Valenciennes, 59300 France
Eligibility Criteria
Inclusion Criteria: * Women aged 18 and over * Having completed chemotherapy (intravenous) for breast cancer (any stage) less than 12 months prior to inclusion * Having a perceived cognitive complaint that appeared during or after (\< 3 months) chemotherapy treatments (no restriction on the care protocol used) and confirmed by a FACT-Cog score compatible with a subjective cognitive disorder (score \< 117 for patients aged 18 to 49; score \< 113 for patients aged 50 to 69; score \<105 for patients aged 70 and over) * Patient eligible for photobiomodulation sessions * Patient with sufficient command of the French language to complete the study questionnaries * Patient having given written consent to participate in the trial * Socially insured patient * Patient willing to comply with all study procedures and duration Exclusion Criteria: * Known cognitive disorders prior to chemotherapy treatment * Patients with psychiatric or psychobehavioral disorders incompatible with photobiomodulation sessions * Patients who, in the 12 months prior to inclusion or at the time of inclusion, have already received photobiomodulation treatment involving "whole body" therapy (photobiomodulation in a phototherapy booth). * Patient having previously received photobiomodulation with cortical stimulation (panel or helmet) with no time limit. * Patient taking or having received capecitabine * Patients taking part in a protocol involving a drug likely to affect cognitive performance (on the investigator's advice). * Patients suffering from claustrophobia * Patient unable to read and/or unable to complete a questionnaire, in the opinion of the investigator
Conditions Glaucoma
Phase PHASE2
Enrollment 138
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to determine whether oral supplementation with different nicotinamide adenine dinucleotide (NAD) precursors can improve visual function in adults with primary open-angle glaucoma. The main questions it aims to answer are: 1. Does daily oral administration of equimolar doses of nicotinamide riboside (NR), nicotinamide (NAM), nicotinamide mononucleotide (NMN), or nicotinic acid (NA) improve visual field sensitivity in glaucoma patients over the short term? 2. How do plasma NAD+ metabolite profiles change after administration of each precursor, and do these changes relate to improvements in visual function? Researchers will compare NR, NAM, NMN, NA, and placebo groups to see if any of the NAD precursors lead to greater improvements in visual field sensitivity or changes in blood NAD+ metabolite levels compared to placebo. Participants will: Be randomly assigned to receive one of the four NAD precursors or placebo daily for two weeks. Undergo comprehensive eye examinations, including visual field testing and optical coherence tomography, at baseline and after two weeks. Provide blood samples before and after the intervention for measurement of NAD+ metabolites. Have safety monitored through clinical examination. This study will help identify whether boosting NAD+ levels with specific precursors offers functional benefit in glaucoma, and which blood metabolites may mediate these effects.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Nicotinamide Riboside — Oral supplementation of 300mg Nicotinamide Riboside (NR) daily for 2 weeks
  • Dietary Supplement: Nicotinamide — Oral supplementation of 125mg Nicotinamide/Niacinamide (NAM) daily for 2 weeks
  • Dietary Supplement: Nicotinamide Mononucleotide — Oral supplementation of 350mg Nicotinamide Mononucleotide (NMN) daily for 2 weeks
  • Dietary Supplement: Nicotinic Acid — Oral supplementation of 350mg Nicotinic Acid (NA) daily for 2 weeks
  • Other: Placebo (Corn Starch) — Oral supplementation of 300mg Placebo daily for 2 weeks
  • Other: Placebo (Corn Starch) — Oral supplementation of 300mg Placebo daily for 2 weeks

Primary Outcomes

  • Change in visual field sensitivity (2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-05-19
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 138 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Christopher Kai Shun Leung
Principal Investigators:
  • Christopher Kai-shun LEUNG, MD (PRINCIPAL_INVESTIGATOR) - The University of Hong Kong
Contact Information
Study Contact:
Christopher Kai-shun LEUNG, MD
(852)3910-2673
cleung21@hku.hk
Nate CHAN
(852)3910-3906
natechan@hku.hk
Kai-shun Christopher LEUNG, MD
(852)3910-3898
cleung21@hku.hk
HKU Eye Centre
Interventions
  • Dietary Supplement: Nicotinamide Riboside — Oral supplementation of 300mg Nicotinamide Riboside (NR) daily for 2 weeks
  • Dietary Supplement: Nicotinamide — Oral supplementation of 125mg Nicotinamide/Niacinamide (NAM) daily for 2 weeks
  • Dietary Supplement: Nicotinamide Mononucleotide — Oral supplementation of 350mg Nicotinamide Mononucleotide (NMN) daily for 2 weeks
  • Dietary Supplement: Nicotinic Acid — Oral supplementation of 350mg Nicotinic Acid (NA) daily for 2 weeks
  • Other: Placebo (Corn Starch) — Oral supplementation of 300mg Placebo daily for 2 weeks
Study Locations (1 sites)
HKU Eye Centre, Wong Chuk Hang, Hong Kong
Eligibility Criteria
Inclusion Criteria: * glaucoma patients * age ≥ 18 years * best corrected VA ≥20/40 * IOP \<21 mmHg * visual field mean deviation better than -24 dB on standard automated perimetry 24-2 SITA standard Exclusion Criteria: * pathological myopia * diseases that may cause visual field loss or optic disc abnormalities other than glaucoma * inability to perform reliable visual field * suboptimal quality of OCT images * diabetic retinopathy/maculopathy * history of abnormal liver function within 12 months * known allergy to NAD precursor supplement(s) * pregnancy or lactation * use of NAD precursor supplements 14 days prior to baseline.
Conditions Medication Adherence, Hypertension, Habi...
Phase NA
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to determine the effectiveness of a novel mobile health-based habit formation intervention for increasing and maintaining adherence to anti-hypertensive (AH) medication among people living with hypertension and indicate medication nonadherence. The main questions it aims to answer are: * Can daily incentives for AH pill taking increase and maintain AH medication adherence, control blood pressure, and reduce healthcare utilization and costs? * Can daily incentives for AH pill taking, combined with action planning (e.g., "After I drink my morning coffee, I will take my medication.") increase and maintain medication adherence, control blood pressure, and reduce healthcare utilization and costs? * What aspects of daily incentives and/or action planning do participants find most helpful or effective for AH medication adherence? * What barriers exist for participants who receive daily incentives and/or action planning? Researchers will compare three study groups: those who only receive daily incentives for the AH pill taking, those who receive daily incentives for AH pill taking combined with action planning, and a control group (who do not receive daily incentives for AH pill taking or action planning). By comparing these three groups, the researchers will be able to determine the effectiveness of the daily incentives with or without action planning for promoting long-term AH medication adherence, reduce healthcare costs, and improve blood pressure. Participants will: * Complete 5 online surveys over the course of 2 years (baseline, month 4, month 8, month 12, month 24). * Submit blood pressure reading for 7 consecutive days after each survey timepoint. * Submit photo evidence of their AH pill taking for 4 months (intervention groups only). The highest- and lowest-performing participants in each intervention group will also be invited to complete a 30-minute interview to identify additional factors that contributed to either successful or unsuccessful completion of the intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Wellth App — Participants will be eligible to receive $30 at the end of four consecutive 30-day periods ($120 in total) if they demonstrate complete medication adherence through the Wellth app (i.e. taking a daily picture of their pills in their hand and submitting it through the Wellth app). Photos must be submitted within a 2-hour window around a specific time of day chosen by the participant and set at the start of each 30-day period. They will lose $2 (from their $30 total) for every day they miss a medication check-in within their pre-set 2-hour window with the Wellth app. The Wellth app will also provide reminders at the end of the day if participants have not yet completed their daily check-in.
  • Behavioral: Action Planning — Participants will learn about habits and the importance of contextual cues for triggering their AH pill taking, and be asked to complete an electronic worksheet with a detailed description of their personalized contextual cue in terms of its: 1) location (e.g., where in the participant's house or office does this cue occur); 2) time of day; 3) preceding action (e.g., "I usually go to the bathroom before making coffee"); and 4) a visual cue (e.g., "my coffee cup will trigger pill taking").
  • Behavioral: Wellth + Cue — Participants will be eligible to receive $30 at the end of four consecutive 30-day periods ($120 in total) if they submit daily evidence of their medication adherence habit using the Wellth app (i.e. one photo that provides evidence of pill-taking and one photo that provides evidence of their contextual cue, which participants will select and specify on their comprehension survey at the start of the study). Photos must be submitted within a 2-hour window around a specific time of day chosen by the participant and set at the start of each 30-day period. They will lose $2 (from their $30 total) for every day they miss a medication check-in (plus evidence of their contextual cue) within their pre-set 2-hour window with the Wellth app. The Wellth app will also provide reminders at the end of the day if participants have not yet completed their daily check-in.

Primary Outcomes

  • Medication Adherence (24 months prior to the study through the 24-month study period)
  • Cardiovascular Health (Baseline, after the 4-month intervention, 8-month follow-up, 12-month follow-up, and 24-month follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-01
Completion: 2029-03-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chad Stecher@asu.edu
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), Wellth Inc., Arizona State University
Contact Information
Study Contact:
Chad D Stecher, PhD
602-496-0957
chad.stecher@asu.edu
Wellth Support Team
(844) 334-7360
help@wellthapp.com
Wellth Inc.
Interventions
  • Behavioral: Wellth App — Participants will be eligible to receive $30 at the end of four consecutive 30-day periods ($120 in total) if they demonstrate complete medication adherence through the Wellth app (i.e. taking a daily picture of their pills in their hand and submitting it through the Wellth app). Photos must be submitted within a 2-hour window around a specific time of day chosen by the participant and set at the start of each 30-day period. They will lose $2 (from their $30 total) for every day they miss a medication check-in within their pre-set 2-hour window with the Wellth app. The Wellth app will also provide reminders at the end of the day if participants have not yet completed their daily check-in.
  • Behavioral: Action Planning — Participants will learn about habits and the importance of contextual cues for triggering their AH pill taking, and be asked to complete an electronic worksheet with a detailed description of their personalized contextual cue in terms of its: 1) location (e.g., where in the participant's house or office does this cue occur); 2) time of day; 3) preceding action (e.g., "I usually go to the bathroom before making coffee"); and 4) a visual cue (e.g., "my coffee cup will trigger pill taking").
  • Behavioral: Wellth + Cue — Participants will be eligible to receive $30 at the end of four consecutive 30-day periods ($120 in total) if they submit daily evidence of their medication adherence habit using the Wellth app (i.e. one photo that provides evidence of pill-taking and one photo that provides evidence of their contextual cue, which participants will select and specify on their comprehension survey at the start of the study). Photos must be submitted within a 2-hour window around a specific time of day chosen by the participant and set at the start of each 30-day period. They will lose $2 (from their $30 total) for every day they miss a medication check-in (plus evidence of their contextual cue) within their pre-set 2-hour window with the Wellth app. The Wellth app will also provide reminders at the end of the day if participants have not yet completed their daily check-in.
Study Locations (1 sites)
Wellth Inc., Los Angeles, California 90292 United States
Eligibility Criteria
Eligibility Criteria: * Aged 18 years or older * Currently diagnosed with hypertension (either stage I or stage II hypertension) * Able to read/write/understand English * Have daily access to a smartphone * Engaged in hypertension care: Already been prescribed hypertension medication for a minimum of 6 months at the time of study enrollment * Demonstrated AH medication nonadherence by having over 73 days without documented AH medication prescription coverage (observable in Arizona Health Care Cost Containment System (AHCCCS) prescription drugs claims) in the past 12 months (i.e. \<80% mean adherence)
Conditions Pulmonary Arterial Hypertension (PAH)
Phase PHASE1
Enrollment 15
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Artesunate — Participants will receive artesunate capsules. Participants will receive artesunate capsules TID in a dose escalation manner (60 mg, 120 mg, 180 mg total daily).

Primary Outcomes

  • Number of Participants with treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs) (16 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-04-01
Completion: 2029-01-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Joseph C. Wu
Principal Investigators:
  • Roham Zamanian, MD (STUDY_DIRECTOR) - Stanford University
Contact Information
Study Contact:
Roham Zamanian, MD
(650) 725-7061
roham.zamanian@stanford.edu
Stanford University
Interventions
  • Drug: Artesunate — Participants will receive artesunate capsules. Participants will receive artesunate capsules TID in a dose escalation manner (60 mg, 120 mg, 180 mg total daily).
Study Locations (1 sites)
Stanford University, Stanford, California 94305 United States
Eligibility Criteria
Inclusion Criteria * Each participant must meet the following criteria to be enrolled in this study: * Adults aged 18 to 75 years. * WHO functional class I, II/III despite treatment with maximally tolerated doses of 2 or more treatment modalities including PDE5 inhibitors, guanylate cyclase stimulators, endothelin receptor antagonists, and prostanoids when appropriate. Exclusion Criteria * Participants who meet any of the following criteria will be excluded from the study. * Participants with serious concomitant morbidity per investigator assessment.
Conditions Mild to Moderate Anxiety and Depression
Phase NA
Enrollment 2400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Anxiety and depression are highly prevalent mental health disorders that impose a significant burden on individuals and public health systems worldwide (GBD 2019 Mental Disorders Collaborators, 2022). Although many existing treatments focus on symptom reduction through targeting negative emotions, fewer interventions specifically enhance positive emotional experiences, despite growing evidence that low positive affect is a key feature of both anxiety and depression. Face-to-face psychologist-led positive affect therapy (PAT) is a promising intervention that aims to cultivate positive emotions, engagement, and meaning, potentially leading to greater improvements in emotional well-being than traditional approaches (Craske et al., 2019). However, empirical evaluations of digitally-delivered, asynchronously-coached, scalable versions of the PAT remain limited (Craske et al., 2024; Firth et al., 2017). The present study thus aims to investigate the comparative efficacy of a digital positive affect intervention (PAI) in reducing symptoms of anxiety and depression and enhancing overall mental health outcomes. We utilize a two-arm randomized controlled trial (RCT) design to investigate the effectiveness of a six-week digitally delivered positive affect intervention (vs. self-monitoring active control; Zainal \& Newman, 2023) in reducing self-reported symptoms of anxiety and depression, as well as other secondary psychosocial outcomes, including sleep quality, quality of life, and emotion regulation. The treatment program comprises weekly evidence-based therapeutic material delivered online, and daily mental health (MH) mobile application prompts delivered thrice a day for the 6-week treatment period, based on evidence-based positive affect therapy principles. The active comparator comprises self-monitoring MH mobile application prompts for the 6-week treatment period. All participants will be assessed on several psychosocial outcomes at mid-treatment, post-treatment, and at 3-, 6-, and 12-month follow-up. The study hypothesizes that participants randomized to the digital PAI will experience greater improvement in anxious and depressive symptoms both immediately after treatment and up to a year later, compared to the self-monitoring MH app. Findings will contribute to growing evidence that digital PAI is an efficacious and feasible treatment to target and enhance positive emotions and related mental health outcomes in adults experiencing anxiety and depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Digital positive affect intervention (PAI) — The Positive Affect Intervention (PAI) is a fully digital, self-guided program uniquely designed to deliver weekly 30-minute online sessions focused on cultivating positive emotions, meaning, and engagement, alongside daily ecological momentary prompts delivered thrice daily over six weeks. Distinctively, the intervention seamlessly integrates multimedia content (e.g., brief weekly videos introducing each session's core principles), practical exercises, and in-the-moment reflection, aiming to reinforce positive affect skills in real time. Its structure not only emphasizes proactive skill application through digital reminders but also systematically assesses user engagement and perceived helpfulness via ecological momentary assessments and post-session feedback questionnaires. Unlike conventional digital interventions that primarily focus on symptom reduction through passive content consumption, this PAI leverages continuous ecological momentary engagement via a dedicated mobile app, e
  • Behavioral: Self-monitoring intervention — The self-monitoring intervention serves as an active comparator designed to isolate the effects of mood self-awareness without introducing therapeutic content. Participants in this arm receive daily prompts via the Qualtrics mEMA mobile app, three times per day over a six-week period, instructing them to track their mood and emotional states through brief ecological momentary assessments (EMAs). Unlike the digital positive affect intervention, this arm does not include psychoeducational material, skills training, or active enhancement strategies; instead, it focuses solely on routine self-monitoring to control for digital engagement and expectancy effects. This minimalist structure allows for a clean contrast between passive self-observation and active therapeutic engagement, enabling robust evaluation of the added value of the Positive Affect Intervention beyond self-monitoring alone

Primary Outcomes

  • Change from baseline Generalized Anxiety Disorder Symptoms at 6 weeks post-randomization (Baseline to 6 weeks post-randomization)
  • Change from baseline Generalized Anxiety Disorder symptoms at 3, 6, and 12 months post-randomization (Baseline to 3 months, 6 months, and 12 months post-randomization)
  • Change from baseline depressive symptoms at 6 weeks post-randomization (Baseline to 6 weeks post-randomization)
  • Change from baseline depressive symptoms at 3, 6, and 12 months post-randomization (Baseline to 3 months, 6 months, and 12 months post-randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-01
Completion: 2029-06-30
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National University of Singapore
Contact Information
Study Contact:
Nur Hani Zainal, Ph.D., M.A.
+6565161126
hanizainal@nus.edu.sg
Sarah Josephine Rajendra, B.S.
+6565161126
sarah.jr@nus.edu.sg
Nur Hani Zainal, Ph.D.
+6565161126
hanizainal@nus.edu.sg
National University of Singapore (NUS)
Interventions
  • Behavioral: Digital positive affect intervention (PAI) — The Positive Affect Intervention (PAI) is a fully digital, self-guided program uniquely designed to deliver weekly 30-minute online sessions focused on cultivating positive emotions, meaning, and engagement, alongside daily ecological momentary prompts delivered thrice daily over six weeks. Distinctively, the intervention seamlessly integrates multimedia content (e.g., brief weekly videos introducing each session's core principles), practical exercises, and in-the-moment reflection, aiming to reinforce positive affect skills in real time. Its structure not only emphasizes proactive skill application through digital reminders but also systematically assesses user engagement and perceived helpfulness via ecological momentary assessments and post-session feedback questionnaires. Unlike conventional digital interventions that primarily focus on symptom reduction through passive content consumption, this PAI leverages continuous ecological momentary engagement via a dedicated mobile app, e
  • Behavioral: Self-monitoring intervention — The self-monitoring intervention serves as an active comparator designed to isolate the effects of mood self-awareness without introducing therapeutic content. Participants in this arm receive daily prompts via the Qualtrics mEMA mobile app, three times per day over a six-week period, instructing them to track their mood and emotional states through brief ecological momentary assessments (EMAs). Unlike the digital positive affect intervention, this arm does not include psychoeducational material, skills training, or active enhancement strategies; instead, it focuses solely on routine self-monitoring to control for digital engagement and expectancy effects. This minimalist structure allows for a clean contrast between passive self-observation and active therapeutic engagement, enabling robust evaluation of the added value of the Positive Affect Intervention beyond self-monitoring alone
Study Locations (1 sites)
National University of Singapore (NUS), Singapore, 117571 Singapore
Eligibility Criteria
Inclusion criteria * Adults aged between 21 and 64 years * Proficient in written and spoken English * Ability to provide informed consent * Scores between 5 and 14 on the Generalized Anxiety Disorder-7 (GAD-7) scale OR * Scores between 5 and 19 on the Patient Health Questionnaire-9 (PHQ-9) scale * Scores below 6 on the Altman Self-Rating Mania (ASRM) scale * Possess an active smartphone with a valid Singapore phone number * Mainly based in Singapore, within the next 15 months Exclusion criteria * Failure to meet the above inclusion criteria * Significant suicidal thoughts within the past two weeks, defined as self-reporting "more than half the days" or "nearly every day" on the PHQ-9 Item 9. * Received psychiatric diagnoses of bipolar disorder, disorders of psychosis, severe clinical anxiety, or severe clinical depression. * Severe clinical anxiety (scores of 15 to 21 on the GAD-7) * Severe clinical depression (scores of 20-27 on the PHQ-9)
Conditions Depression, Major Depressive Disorder
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn how different types of non-invasive brain stimulation affect mood and brain function in adults with major depressive disorder (MDD). It will also study how brain stimulation may work together with antidepressant treatments. The main questions this study aims to answer are: How do different patterns of brain stimulation affect mood in people with depression? Do brain networks involved in emotion and self-reflection respond differently depending on the type of stimulation? What are the combined effects of brain stimulation and antidepressant treatments on mood and brain activity? Researchers will compare different brain stimulation patterns and target areas to understand their individual and combined effects. Participants will: Receive three types of brain stimulation (intermittent, continuous, and sham) in different sessions Undergo MRI scans during the administration of either a fast-acting or conventional antidepressant. Complete mood assessments during the scan and for one week after each session This study may help identify brain-based strategies to improve treatment for depression. In addition, a subset of participants (\~10) will complete a reward-guided decision-making fMRI task for feasibility purposes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Other Masking/blinding: Double

Interventions / Regimen

  • Device: Intermittent theta burst stimulation — Aimed at potentiating the stimulation target.
  • Device: Sham theta burst stimulation — No effect is expected on stimulation target
  • Device: Continuous theta burst stimulation — Aimed at depotentiating the stimulation target

Primary Outcomes

  • Bold Signal Change in the Salience Network During the fMRI Experiment (Assessed at approximately day 7, day 14, and day 21 following baseline.)
  • BOLD Signal Change in the Default Mode Network During the fMRI Experiment (Assessed at approximately day 7, day 14, and day 21 following baseline.)
  • Changes in Mood Ratings Following TBS and the fMRI Experiment (Baseline)
  • Subcute Mood Change Following TBS and the fMRI experiment (Approximately at day 7, 14, and 21)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-15
Completion: 2030-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Marta Peciña, MD PhD
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Marta Pecina, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Eli Strohecker, BS
412-246-6147
stroheckereg@upmc.edu
Gaurav Badhan, BS
badhang@upmc.edu
Eli Strohecker, BS
412- 246-6147
stroheckereg@upmc.edu
Bellefield Towers
Interventions
  • Device: Intermittent theta burst stimulation — Aimed at potentiating the stimulation target.
  • Device: Sham theta burst stimulation — No effect is expected on stimulation target
  • Device: Continuous theta burst stimulation — Aimed at depotentiating the stimulation target
Study Locations (1 sites)
Bellefield Towers, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion criteria: 1. Adults ages 18-55 (\~60% female). 2. Diagnosis of Major Depressive Disorder (MDD) with or without comorbid anxiety disorders (e.g., panic disorder) or Axis II disorders. 3. Psychotropic-free at enrollment. Exclusion Criteria: 1. being pregnant or breastfeeding; 2. diagnosis of psychotic depression, schizophrenia, bipolar disorder, or other Axis I disorders, except for anxiety disorders; 3. severe substance use (excluding nicotine) in the last 2 months as determined by using the MINI, a structured interview that uses the Diagnostic and Statistical Manual of Mental Disorders; 4. requiring immediate hospitalization; 5. epilepsy or conditions requiring an anticonvulsant; 6. receiving vagus nerve stimulation, electroconvulsive therapy (ECT), or TMS in the last 2 months; 7. currently taking or have taken within the last 21 days psychiatric medication or augmenting agents; 8. receiving depression-specific psychotherapy; 9. actively suicidal or considered a high suicide risk; 10. enrolled in another study; or 11. MRI/TMS contraindication as determined by the fMRI and TMS screening questionnaires
Conditions Intra-Abdominal Hypertension
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to investigate the intra-abdominal pressure utilizing the Accuryn monitoring system during pulsed field ablation procedures in the electrophysiology lab compared to the type of anesthetic utilized.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: Accuryn Foley catheter device — Accuryn foley catheter placed on all subjects after consent who are having treatment for atrial flutter or atrial fibrillation

Primary Outcomes

  • Intra-abdominal pressure under Pulsed Field Ablation (PFA) under general anesthesia (hour 2)
  • Intra-abdominal pressure under Pulsed Field Ablation (PFA) under sedation (hour 2)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-03
Completion: 2026-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wake Forest University Health Sciences
Principal Investigators:
  • Karuna Rajkumar, MD (PRINCIPAL_INVESTIGATOR) - Wake Forest University Health Sciences
Contact Information
Study Contact:
Karuna Rajkumar, MD
832-707-0858
kputturr@wakehealth.edu
Karuna Rajkumar
832-707-0858
kputturr@wakehealth.edu
Wake Forest Health Sciences
Interventions
  • Device: Accuryn Foley catheter device — Accuryn foley catheter placed on all subjects after consent who are having treatment for atrial flutter or atrial fibrillation
Study Locations (1 sites)
Wake Forest Health Sciences, Winston-Salem, North Carolina 27157 United States
Eligibility Criteria
Inclusion Criteria: * Adult patients receiving pulse field ablation procedures for standard of care treatment of atrial fibrillation and/or atrial flutter. * Eligible for Foley catheter placement with no contraindications to Intra-abdominal pressure (IAP) monitoring. Exclusion Criteria: * Patients under the age of 18 will be excluded. * History of intra-abdominal surgery within the past 6 months. * Known contraindications to bladder catheterization or catheter ablation; history of prostate issues / Benign prostatic hyperplasia (BPH) or frequent urinary tract infections * Pregnant or breastfeeding individuals * History of chronic obstructive pulmonary disease (COPD) with home oxygen use
Conditions Diabetes Mellitus, Type 2, Diabetic Foot...
Phase Not Applicable
Enrollment 8000
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical investigation is to explore a non-invasive technology for measuring the microcirculatory structure, composition and function in patients from a primary care population. The main aims are: 1. To evaluate the robustness of the technology for assessment of the molecular composition and structure of the skin tissue and microcirculatory function, on a prospective primary care population. 2. To evaluate the device and method on its capability to detect deficiencies in circulation, compared with existing reference systems with similar characteristics for patients with known cardiovascular disease risk and/or diabetes.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Association between IMD-derived variables and markers for circulatory deficiencies measured by CE-marked reference systems (Same day as enrolment, or typically within 3-6 months from enrolment. If 1-year follow-up, then 1 year and 3-6 months from enrolment.)
  • Performance of a combined risk score using data from Spectrum 1 and the in parallel performed investigation "Cardio Alpha"(CIV-ID: CIV-22-08-040426) (Same day as enrolment or typically within 3-6 months following enrolment. If 1-year follow-up, then typically 1 year and 3-6 months from enrolment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-02-01
Completion: 2026-01-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 8000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: HJN Sverige AB/Neko Health
Principal Investigators:
  • Samuel Rodgers, MD (PRINCIPAL_INVESTIGATOR) - HJN Sverige AB/Neko Health AB
Contact Information
Study Contact:
Mattias Windå, MSc
+46703169040
mattias@nekohealth.com
Andreea Valdman, MD
+4673 939 27 11
andreea@nekohealth.com
Atrium Health Care Centre
Samuel Rodgers, MBBS
Atrium Health Care Centre
Interventions
N/A
Study Locations (3 sites)
Atrium Health Care Centre, Stockholm, Sweden
Neko Health Centre, Regeringsgatan, Stockholm, Sweden
Neko Health Centre, Sibyllegatan, Stockholm, Sweden
Eligibility Criteria
Inclusion Criteria: * Adult patients part of the regular healthcare patient flow at the investigational sites, or as separately invited to participate in this investigation. * Patients with signed informed consent Exclusion Criteria: * Cognitive impairment * Patients unable to understand the oral and written study information in Swedish or English * Other severe disorder or terminal disease * Patients unable to provide an informed consent * Patient´s with damaged, scarred or non-intact skin within the skin area of interest.
Conditions Lung Cancer, Cancer of the Lung
Phase Not Applicable
Enrollment 279
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The investigators proposal is ripe for executing as the investigators seek to leverage this "natural experiment" initiated by the BJC health system to evaluate the effectiveness of the Pink \& Pearl Campaign as an implementation strategy to promote lung cancer screening (LCS) uptake among LCS-eligible women undergoing mammography at BJC West County. This evaluation is grounded in the Integrated Screening Action Model that depicts individual- and environmental-level influences on the screening behavior process. Using an explanatory sequential mixed methods design, which combines both quantitative and qualitative approaches, the research questions and specific aims for this proposal are to: a) evaluate the baseline prevalence of LCS among LCS-eligible women; b) assess whether the Pink \& Pearl Campaign increases referrals and uptake/ completion of LCS among LCS-eligible women undergoing screening mammography; and c) evaluate individual and environmental factors influencing LCS uptake, and implementation outcomes of the campaign. These implementation outcomes will help identify whether the campaign was put in place successfully or not. This proposal will inform strategies for integrating cancer screening programs to improve poorly performing programs like LCS.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Prevalence of LCS-eligible women who opt-in to, and successfully, complete LCS mammography and opt-in to lung cancer screening (At baseline)
  • Number of women screened for LCS (At 3 months)
  • Number of women screened for LCS (At 6 months)
  • Feasibility of Pink and Pearl project (At 6 months)
  • Acceptability of Pink and Pearl project (At 6 months)
  • Appropriateness of Pink and Pearl project (At 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-08
Completion: 2027-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 279 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Washington University School of Medicine
Principal Investigators:
  • Beryne Odeny, M.D., MPH, Ph.D. (PRINCIPAL_INVESTIGATOR) - Washington University School of Medicine
Contact Information
Study Contact:
Beryne Odeny, M.D., MPH, Ph.D.
314-362-1183
beryne@wustl.edu
Beryne Odeny, M.D, MPH, Ph.D.
314-362-1183
beryne@wustl.edu
Barnes-Jewish Hospital West County
Beryne Odeny, M.D., MPH, Ph.D.
Barnes-Jewish Hospital West County
Interventions
N/A
Study Locations (1 sites)
Barnes-Jewish Hospital West County, Creve Coeur, Missouri 63141 United States
Eligibility Criteria
Inclusion Criteria for Participants: * Undergoing screening mammography * Between the ages of 50-80 years (inclusive) * Reporting a 20 pack-year equivalent of either current smoking history or have quit in the past 15 years * Can speak and understand English * Ability to understand willingness to provide informed consent. Exclusion Criteria for Participants: * Diagnosed with a serious health problem that will likely limit life expectancy (such as previous history of lung cancer, symptoms of lung cancer such as hemoptysis or unexplained weight loss of more than 6.8 kg (15 lb) in the previous year) * Subjects with symptoms of lung cancer should get a diagnostic CT scan * Unable or unwilling to get treatment if lung cancer is found Eligibility Criteria for Providers: * Older than 20 years of age
Conditions Depression - Major Depressive Disorder, ...
Phase Not Applicable
Enrollment 560
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Behavioural Development, Long-term Outcomes and Opportunities to Optimize Youth Mental Health (BLOOM) is a project that aims to overcome age and diagnostic boundaries to generate person-specific longitudinal profiles of mental health in youth aged 9 to 25. The overarching objective is to lay the informational foundation to accurately predict both clinical outcomes and opportunities to optimize health trajectories. This project will recruit youth in need without any mental health diagnosis and follow them annually for 5 years. The present study includes assessment of antecedents, opportunities and outcomes that will establish eligibility for preventive interventions

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Number of new onsets of one of the seven mental illnesses as per DSM-5 criteria (From screening to 5 years of follow-up.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-07-01
Completion: 2029-07-01
Eligibility
Age: 9 Years and older
Sex: ALL
Volunteers: true
Enrollment: 560 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Douglas Mental Health University Institute
Contact Information
Study Contact:
Céline Villemus Project Manager, Msc
514-761-6131
celine.villemus.comtl@ssss.gouv.qc.ca
Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal
Interventions
N/A
Study Locations (1 sites)
Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montreal, Quebec H4H 1R3 Canada
Eligibility Criteria
Inclusion Criteria: Youth between 9 to 25 years of age at inclusion, who are able to read and understand either French or English, with at least one parent or legal guardian available to consent for those under 18 years of age. Specific eligibility criteria: Help-seeking group: At least one help-seeking contact made with a primary care clinical service provider or agency (e.g, paediatric/family physician clinic, CLSC or Aire Ouverte) for a mental health concern (i.e., clinical needs). Non help-seeking group: At least one of the birth parents or siblings have received psychiatric care for a diagnosis of DMDs (i.e., family needs) OR Being in contact with community agencies that provide youth-centred social services for food, housing, social discrimination (e.g., racialized youth, LGBTQ2SIA+) (i.e., social needs) OR Having a diagnosed chronic physical illness that is expected to require treatment for \>12 months (e.g., diabetes, asthma to name a few) (i.e., physical health needs) Exclusion Criteria: * Due to the requirements of assessment procedures, youth who cannot communicate verbally due to known neurological conditions or intellectual disabilities will not be included. Youth who are already diagnosed with one of the DMDs by a physician and currently prescribed a treatment targeting the diagnosed condition (pharmacological or psychotherapeutic interventions), will not be eligible for inclusion. Importantly, no one will be excluded based on sex, gender, health insurance status, ethnicity, income status, ability to travel or living arrangements. If a participant initially approached through the referral pathways for non help-seeking individuals turns out to have had at least one help-seeking contact for a mental health concern (i.e., clinical needs), the participant will still be included but classified as part of the help-seeking group. We anticipate non help-seeking referrals to satisfy more than one criteria. Their occurrence and distribution will be recorded in detail as part of our assessment procedure.
Conditions Anatomic Stage II Breast Cancer AJCC v8,...
Phase PHASE1
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase I trial studies the performance, including ultrasound visibility, of an optimized ultrasound twinkling marker in imaging lymph nodes in patients with clinically node-positive breast cancer. In patients with biopsy-proven breast cancer, biopsy markers are used to identify the sites of cancer involvement in both the breasts and lymph nodes. These biopsy markers are critical for guiding surgical management many months after the marker is placed. For breast radiologists and breast surgeons, there is a need for simple, consistent visibility of biopsy markers by ultrasound, particularly several months after marker placement. Ultrasound is the imaging method of choice, particularly for lymph nodes in the armpit (axilla). Ultrasound is non-ionizing and is more comfortable for patients compared to mammography. However, ultrasound visibility of these markers is challenging and inconsistent, with ultrasound failing to detect the marker approximately 25% of the time. The Mayo-designed investigational biopsy marker takes advantage of an ultrasound phenomenon called twinkling artifact. The Mayo-designed optimized ultrasound twinkling marker may work better than standard biopsy clip marker in imaging lymph nodes in patients with clinically node-positive breast cancer.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Device Feasibility Masking/blinding: None

Interventions / Regimen

  • Procedure: Diagnostic Mammography — Undergo mammography
  • Procedure: Resection — Undergo surgical resection of the lymph node as part of standard care.
  • Procedure: Ultrasound Imaging — Undergo ultrasound imaging. Ultrasound images will be evaluated for presence and visibility/conspicuity of the twinkling marker.
  • Device: Twinkling Marker Placement — Undergo ultrasound-guided placement of the optimized twinkling marker into the positive lymph node after confirmation of metastatic axillary lymph node involvement.

Primary Outcomes

  • Conspicuity of the optimized Mayo-developed twinkling marker (Baseline up to final pre-operative imaging before surgery; generally 6-9 months)
  • Migration of the optimized Mayo-developed twinkling marker (At time of surgery (baseline))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-08-29
Completion: 2027-11-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Collaborators: National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Principal Investigators:
  • Christine U. Lee, MD, PhD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic in Rochester
Contact Information
Study Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Breast and Melanoma Surgical Oncology (BSMO) Clinical Research Unit
507-538-4849
BMSORESEARCH@mayo.edu
Shelley Fabian
507-538-4849
BMSORESEARCH@mayo.edu
Mayo Clinic in Rochester
Interventions
  • Procedure: Diagnostic Mammography — Undergo mammography
  • Procedure: Resection — Undergo surgical resection of the lymph node as part of standard care.
  • Procedure: Ultrasound Imaging — Undergo ultrasound imaging. Ultrasound images will be evaluated for presence and visibility/conspicuity of the twinkling marker.
  • Device: Twinkling Marker Placement — Undergo ultrasound-guided placement of the optimized twinkling marker into the positive lymph node after confirmation of metastatic axillary lymph node involvement.
Study Locations (1 sites)
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * Patient 18 years or older with breast cancer and biopsy-proven malignant involvement of an axillary lymph node * Surgical management will be determined by the surgeon, who will decide if preoperative Iodine (I)-125 seed localization of the positive node is necessary or if they will retrieve the positive node with intraoperative ultrasound guidance. During surgery, the targeted node, its associated biopsy markers, I-125 seed if placed, and optimized twinkling marker will be resected. The position of the marker in the lymph node or proximity to the node will be noted from the surgical and pathology documentation * Surgery will be performed by one of the surgeons in the Division of Breast and Melanoma Surgical Oncology (Doctor \[Dr.\] Judy Boughey, Dr. Amy Degnim, Dr. Tina Hieken, Dr. Jeffrey Johnson, Dr. Mary Mrdutt, Dr. Shon Black) * Patients must be able to understand the study procedures and comply with them for the entire length of the study * No contraception is necessary or required Exclusion Criteria: * Patients who are pregnant * Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements * Current or past participation within a specified timeframe in another clinical trial, as warranted by the administration of this intervention
Conditions Long Covid-19, Emotional Disorder, Anxie...
Phase NA
Enrollment 90
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This Randomized Controlled Trial (RCT) aims to assess the effectiveness and acceptability of the Unified Protocol (UP) in an online group format for the treatment of emotional disorders in adults. Participants will be 90 adults (45 in the control group and 45 in the experimental group) with diagnosis of long COVID and comorbid emotional disorders. Participants will be recruited at Hospital Royo Villanova from Zaragoza, Spain. In this study it will be explored whether the changes obtained after the intervention in emotional disorders and cognitive complaints are maintained over 12 months. Additionally, levels of chronic stress will be longitudinally evaluated in the experimental group through accumulated cortisol levels in hair, before and after the application of the UP.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders — This transdiagnostic psychological intervention is focused on training emotion regulation skills. This program is composed by 8 modules (core modules are 3 to 7). In this study we will use a group online format (videocalls). Each sessin will last 2 hours. The contents of the UP will be distributed in 12 online sessions as follows: * Module 1 (session 1): Setting goals and maintaining motivation. * Module 2 (sessions 2 and 3): Understanding your emotions. * Module 3 (sessions 4 and 5): Mindful Emotions Awareness. * Module 4 (sessions 6 and 7): Flexible thinking. * Module 5 (session 8): Emotional baheviors. * Module 6 (session 9): Facing physical sensations. * Module 7 (sessions 10 and 11): Emotionl exposures. * Module 8 (Session 12): Relapse prevention.
  • Other: Treatment as Usual (TAU) — This intervention will act as a control condition. During the waiting period (12 weeks) participants assigned to this condition will continue receiving Treatment As Usual at the Royo Villanova Hospital. It consists of regular contact with doctors to monitor the physical symptomsof long COVID-19. After the 12 weeks, participants in this conditions will join the experimental group and they will receive the psychological intervention following the same procedure described for the experimental condition.

Primary Outcomes

  • General Depression Severity and Interference Scale (ODSIS; Bentley et al., 2014. Validated in Spanish by Osma et al., 2019) (Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended))
  • General Severity and Interference Scale for Anxiety (OASIS; Norman et al., 2006. Validated in Spanish by Osma et al., 2019) (Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Instituto de Investigación Sanitaria Aragón
Collaborators: Hospital Universitario Royo Villanova
Contact Information
Study Contact:
Jorge Osma Jorge Osma, PhD
+34 978645390
osma@unizar.es
Jorge Osma Jorge Osma, PhD
+34 978645390
osma@unizar.es
Hospital Royo Villanova
Verónica Martínez Borba Verónica Martínez Borba, PhD
Hospital Royo Villanova
Interventions
  • Behavioral: Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders — This transdiagnostic psychological intervention is focused on training emotion regulation skills. This program is composed by 8 modules (core modules are 3 to 7). In this study we will use a group online format (videocalls). Each sessin will last 2 hours. The contents of the UP will be distributed in 12 online sessions as follows: * Module 1 (session 1): Setting goals and maintaining motivation. * Module 2 (sessions 2 and 3): Understanding your emotions. * Module 3 (sessions 4 and 5): Mindful Emotions Awareness. * Module 4 (sessions 6 and 7): Flexible thinking. * Module 5 (session 8): Emotional baheviors. * Module 6 (session 9): Facing physical sensations. * Module 7 (sessions 10 and 11): Emotionl exposures. * Module 8 (Session 12): Relapse prevention.
  • Other: Treatment as Usual (TAU) — This intervention will act as a control condition. During the waiting period (12 weeks) participants assigned to this condition will continue receiving Treatment As Usual at the Royo Villanova Hospital. It consists of regular contact with doctors to monitor the physical symptomsof long COVID-19. After the 12 weeks, participants in this conditions will join the experimental group and they will receive the psychological intervention following the same procedure described for the experimental condition.
Study Locations (2 sites)
Hospital Royo Villanova, Zaragoza, Zaragoza 50015 Spain
Hospital Royo Villanova, Zaragoza, Spain
Eligibility Criteria
Inclusion Criteria: * Residing in Autonomous Community of Aragon (Spain). * Being at least 18 years old. * Understanding of Spanish. * Being diagnosed with long COVID-19: documented SARS-CoV-2 infection and persistence of symptoms beyond 12 weeks after the acute infection. * Symptoms of depression (ODSIS≥7) and/or anxiety (OASIS≥8). * Meeting the criteria for an emotional disorder diagnosis. * Having access to Internet. * Signing the informed consent. Exclusion Criteria: * Pre-existing emotional symptoms prior to the acute SARS-CoV-2 infection. * Actually receiving psychological treatment. * Having a diagnosis of severe mental disorder (e.g., personality disorder, bipolar disorder, etc.). * Active suicidal ideation at the time of the assessment. * Individuals on psychotropic medication must maintain their dosage throughout the study, unless medically contraindicated.